Results 11 to 20 of about 3,759,163 (248)

Chinese Prostate Cancer Consortium (CPCC) Chinese expert consensus on advanced prostate cancer: clinical management of patients with metastatic hormone-sensitive prostate cancer treated by initial novel hormone therapy (2022 edition) [PDF]

Zhongguo aizheng zazhi, 2022
Metastatic hormone-sensitive prostate cancer (mHSPC) is a male health concern requiring continuous attention. In 2021, an important update was included in domestic and international guidelines regarding the recommendations of initial systemic therapy for
Chinese Prostate Cancer Consortium (CPCC), YE Dingwei, HUANG Jian
doaj   +3 more sources

Tyrol Prostate Cancer Demonstration Project : early detection, treatment, outcome, incidence and mortality [PDF]

, 2008
This study aimed to evaluate the effectiveness of a well-controlled programme of early detection and treatment of prostate cancer in the population of Tyrol, Austria, where such a programme of early detection and treatment was initiated in 1988 and where
Severi, Gianluca, Frauscher, Ferdinand, Horninger, Wolfgang, Klocker, Helmut, Schennach, Harald, Tyrol Prostate Canc Screening Grp, Boniol, Mathieu, , Tyrol Prostate Canc Screening Grp, Bektic, Jasmin, Boyle, Peter, Robertson, Chris, Pelzer, Alexandre, Oberaigner, Wilhelm, Schafer, Georg, Bartsch, Georg   +14 more
core   +3 more sources

Examining the influence of illness perception and financial toxicity on the quality of life of prostate cancer patients

African Journal of Urology, 2021
Background Cancer of the prostate (CaP) is a public health problem that affects the male genitourinary system causing a significant threat to men’s quality of life (QoL).
Elizabeth O. Akin-Odanye, Chidiebere N. Ogo, Faoziyat A. Sulaiman, Lawal Suleiman, Motolani E. Ogunsanya, Folakemi T. Odedina   +5 more
doaj   +1 more source

Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes

BMC Urology, 2022
Background To report the feasibility, oncological and functional outcomes of salvage robot-assisted radical prostatectomy (sRARP) for recurrent prostate cancer (PCa) after irreversible electroporation (IRE).
Alexandar Blazevski, William Gondoputro, Matthijs J. Scheltema, Amer Amin, Bart Geboers, Daniela Barreto, Anne-Maree Haynes, Ron Shnier, Warick Delprado, Shikha Agrawal, James E. Thompson, Phillip D. Stricker   +11 more
doaj   +1 more source

Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen

The World Journal of Men's Health, 2023
Purpose: Prostate cancer (PCa) screening can lead to potential over-diagnosis/over-treatment of indolent cancers. There is a need to optimize practices to better risk-stratify patients.
Zoe D. Michael, Srinath Kotamarti, Rohith Arcot, Kostantinos Morris, Anand Shah, John Anderson, Andrew J. Armstrong, Rajan T. Gupta, Steven Patierno, Nadine J. Barrett, Daniel J. George, Glenn M. Preminger, Judd W. Moul, Kevin C. Oeffinger, Kevin Shah, Thomas J. Polascik   +15 more
doaj   +1 more source

The relationship between biochemical recurrence and number of lymph nodes removed during surgery for localized prostate cancer

BMC Urology, 2023
Purpose To assess whether completeness of pelvic lymph node dissection (PLND) as measured by lymph node yield reduces biochemical recurrence (BCR) in men undergoing radical prostatectomy (RP) for prostate cancer (PCa), stratified according to Briganti ...
Paul Doan, Athos Katelaris, Matthijs J. Scheltema, Andrew Hayen, Amer Amin, Amila Siriwardana, Minh Tran, Bart Geboers, William Gondoputro, Anne Maree Haynes, Jayne Matthews, Warick Delprado, Phillip D. Stricker, James Thompson   +13 more
doaj   +1 more source

Prevention and early detection of prostate cancer. [PDF]

, 2014
Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer.
Culig, Zoran, Vecchia, Carlo La, Stenzl, Arnulf, P. H. Brown, Meyskens, FL, H. Schmid, Thorat, M.A., Parnes, Howard L., Wilt, Timothy J, Rittenhouse, H., Minasian, Lori M, Perner, S. (Sven), Schmid, H-P, Cuzick, J, Minasian, LM, Brawley, Otis W., Ford, Leslie G., G. Andriole, Perner, S, Key, Timothy J., D. Ilic, Ilic, Dragan, Parker, C. (C.), Key, TJ, Andriole, Gerald, Hamdy, Freddie C., R. A. Eeles, Holmberg, Lars, J. Schalken, Eeles, R. (Rosalind), Parker, C, Lilja, Hans, Wolk, Alicja, Holmberg, Lars,, Parnes, Howard L, Tombal, B, T. J. Wilt, Schmitz-Dräger, Bernd J., Schmitz-Draeger, BJ, F. H. Schröder, Hamdy, Freddie C, F. C. Hamdy, Lilja, H, Marberger, Michael, Lund University., Hamdy, FC, Schalken, J, Andriole, G.L. (Gerald), Andriole, G, Cuzick, Jack, Hamdy, F. (Freddie), Schmid, HP, Vecchia, C. La, Schmid, Hans Peter, Ford, L.G., A. Wolk, Tombal, Bertrand, Schmid, H.P., Meyskens, F.L. (Frank L), Wilt, TJ, Schmid, H.-P. (Hans-Peter), Thorat, Mangesh A, Brawley, O.W., T. J. Key, Lilja, H., Schalken, J.A. (Jack), Parker, C., Holmberg, L, Schmitz-Dräger, Bernd J, M. Marberger, La Vecchia, C, Key, T.J. (Timothy J), Brawley, OW, F. L. Meyskens, Eeles, Rosalind A, Schröder, F.H. (Fritz), B. J. Schmitz Dräger, Brown, PH, Parker, Chris, Ilic, D, Ilic, D. (Dragan), Ford, L.G. (Leslie G), C.La Vecchia, Wolk, K. (Kerstin), Tombal, B. (Bertrand), Schmitz-Drager, B.J., Minasian, L.M. (Lori M), L. M. Minasian, Schröder, Fritz H, H. Lilja, B. Tombal, Schalken, J.A., Brown, Powel H, Rittenhouse, H. (Harry), O. W. Brawley, Stenzl, A, C. Parker, Brawley, O.W. (Otis W), Meyskens, Frank L., Vecchia, C.L. (Carlo La), Culig, Z., Brown, P.H., Parnes, HL, Cuzick, J., Wilt, Timothy J., Ford, Leslie G, Z. Culig, Culig, Z. (Zoran), L. G. Ford, Brawley, Otis W, Key, Timothy J, Schmitz-Dräger, B.J. (Bernd J), S. Perner, Marberger, M, Schalken, Jack, Thorat, M.A. (Mangesh A), Hamdy, F.C., Stenzl, A. (Arnulf), Wilt, T.J., Wolk, A, Schroder, F.H., Culig, Z, Key, T.J., Eeles, R.A., Lilja, Hans,, Ford, LG, Lilja, H. (Hans), Parnes, H.L. (Howard L), Eeles, RA, Marberger, M., Andriole, G., Schröder, Fritz H., Schmid, Hans-Peter, Stenzl, A., L. Holmberg, Meyskens, F.L., Thorat, Mangesh A., A. Stenzl, Meyskens, Frank L, Brown, P.H. (Powel H), J. Cuzick, La Vecchia, Carlo, H. Rittenhouse, H. L. Parnes, Wolk, A., Rittenhouse, Harry, Perner, Sven, M. A. Thorat, Tombal, B., Schröder, Fritz, Minasian, Lori M., Ilic, D., Minasian, L.M., Parnes, H.L., Rittenhouse, H, Marberger, M. (Michael), Perner, S., Holmberg, L. (Lars), Cuzick, J. (Jack), Wilt, T.J. (Timothy J.), Holmberg, L., Thorat, MA, Eeles, Rosalind A., Brown, Powel H., Marberger M, Schmid HP, Wolk A, Cuzick J, Eeles RA, Ford LG, Ilic D, Key TJ, Stenzl A, Thorat MA, Schalken J, Hamdy FC, Parnes HL, Holmberg L, Schröder FH, Minasian LM, Parker C, Brawley OW, Andriole G, Culig Z, Schmitz-Dräger BJ, Lilja H, Rittenhouse H, La Vecchia C, Tombal B, Perner S, Wilt TJ, Meyskens FL, Brown PH, Schroder, FH, Schmitz-Drager, BJ   +194 more
core   +1 more source

Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. [PDF]

, 2009
Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a cohort of 808 patients diagnosed ...
A Gopalan, M W Kattan, Scardino, P, V Reuter, C Cooper, J Eastham, Eastham, J., Gopalan, A., Cuzick, J, Gerald, W., Gopalan, A, Reuter, V, Ambroisine, L., D M Berney, Kudahetti, S., H Moller, Scardino, P., Reuter, V., Kudahetti, S, Moller, H, Gerald, W, J Cuzick, Berney, D. M., Moller, H.; id_orcid, Møller, H., Cuzick, J., Berney, DM, L Ambroisine, Fisher, G., Eastham, J, Cooper, C., S Kudahetti, P Scardino, Ambroisine, L, Foster, C. S., Fisher, G, Foster, CS, Cooper, C, W Gerald, G Fisher, C S Foster, Kattan, M. W., Kattan, MW   +42 more
core   +1 more source

Exploiting Machine Learning for Predicting Nodal Status in Prostate Cancer Patients [PDF]

, 2013
Prostate cancer is the second cause of cancer in males. The prophylactic pelvic irradiation is usually needed for treating prostate cancer patients with Subclinical Nodal Metestases.
Gatta, Roberto, Bertoni, Filippo, Vallati, Mauro, De Bari, Berardino, Buglione, Michela, Magrini, Stefano, Jereczek-Fossa, Barbara   +6 more
core   +3 more sources

Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea

BMC Cancer, 2018
Background For the expanding population of bladder cancer survivors in Korea, the development of subsequent cancers is a significant concern. Here, we provide the second primary cancer incidence rates and types in Korean patients with bladder cancer ...
Whi-An Kwon, Jae Young Joung, Jiwon Lim, Chang-Mo Oh, Kyu-Won Jung, Sung Han Kim, Ho Kyung Seo, Weon Seo Park, Jinsoo Chung, Kang Hyun Lee, Young-Joo Won   +10 more
doaj   +1 more source